ArticleBioengineering (Basel, Switzerland)2025
A Multi-Stage Framework for Kawasaki Disease Prediction Using Clustering-Based Undersampling and Synthetic Data Augmentation: Cross-Institutional Validation with Dual-Center Clinical Data in Taiwan.
Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Kawasaki disease (KD) is a rare yet potentially life-threatening pediatric vasculitis that, if left undiagnosed or untreated, can result in serious cardiovascular complications. Its heterogeneous clinical presentation poses diagnostic challenges, often failing to meet classical criteria and increasing the risk of oversight. Leveraging routine laboratory tests with AI offers a promising strategy for enhancing early detection. However, due to the extremely low prevalence of KD, conventional models often struggle with severe class imbalance, limiting their ability to achieve both high sensitivity and specificity in practice. To address this issue, we propose a multi-stage AI-based predictive framework that incorporates clustering-based undersampling, data augmentation, and stacking ensemble learning. The model was trained and internally tested on clinical blood and urine test data from Chang Gung Memorial Hospital (CGMH, n = 74,641; 2010-2019), and externally validated using an independent dataset from Kaohsiung Medical University Hospital (KMUH, n = 1582; 2012-2020), thereby supporting cross-institutional generalizability. At a fixed recall rate of 95%, the model achieved a specificity of 97.5% and an F1-score of 53.6% on the CGMH test set, and a specificity of 74.7% with an F1-score of 23.4% on the KMUH validation set. These results underscore the model's ability to maintain high specificity even under sensitivity-focused constraints, while still delivering clinically meaningful predictive performance. This balance of sensitivity and specificity highlights the framework's practical utility for real-world KD screening.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.